The Moat Index
Compare moats, side by side.
Two to four companies, scored on the same five investor questions from their SEC filings — so the comparison is apples to apples. The method is fully public.
PRVA · Healthcare · Narrow moat
On the watchlist
The pricingPower component abstained: Not enough years of gross-margin data to score pricing power. The other four 20% weights were renormalized over the scored 80%.
| Measure | PRVA | HALO | TT | ROK |
|---|---|---|---|---|
| Moat Score (0–100) | 70 (highest) | 70 (highest) | 70 (highest) | 69 |
| Methodology version | moat-index@2.0.0 | moat-index@2.0.0 | moat-index@2.0.0 | moat-index@2.0.0 |
| Business trend | 93 (highest) | 75 | 61 | 51 |
| Pricing power | — | 96 (highest) | 54 | 69 |
| Returns on capital | 26 | 77 | 85 | 100 (highest) |
| Balance-sheet safety | 100 (highest) | 40 | 85 | 59 |
| Capital discipline | 60 | 62 | 64 | 68 (highest) |
| Price vs. high estimate | 1931% above high estimate | 57% above high estimate (largest discount to high estimate) | No price data | 344% above high estimate |
| Market cap | $3.2B | $9.1B | — | $51.6B |
| Moat tier | Narrow moat | Narrow moat | Narrow moat | Narrow moat |
| Filings as of | FY2025 | FY2025 | FY2025 | FY2025 |